Unknown

Dataset Information

Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.


ABSTRACT:

Background

Coagulation disorders and reperfusion of ischemic myocardium are major causes of morbidity and mortality. Lectin pathway initiation complexes are composed of multimolecular carbohydrate recognition subcomponents and 3 lectin pathway-specific serine proteases. We have recently shown that the lectin pathway-specific carbohydrate recognition subcomponent mannose-binding lectin plays an essential role in the pathophysiology of thrombosis and ischemia/reperfusion injury. Thus, we hypothesized that the endogenous mannose-binding lectin (MBL)/ficolin-associated protein-1 (MAP-1) that inhibits complement activation in vitro also could be an in vivo regulator by attenuating myocardial schema/reperfusion injury and thrombogenesis when used at pharmacological doses in wild-type mic

SUBMITTER: Pavlov VI 

PROVIDER: S-EPMC3500764 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature